Additionally, complementary studies in TRAMP-C1 prostate cancer models confirm NFE2L2 reactivation using DNMT inhibitor 5-aza-2′-deoxycytidine and histone deacetylase inhibitor Trichostatin A [139,140]. The gene discussed is NFE2L2; the disease is prostate cancer.